AETHLON MEDICAL INC 10-K — AI Bull & Bear Analysis

The 10-K filing presents a classic biotech trade-off: a high-upside, platform-based technology versus an unstable financial base. Aethlon's ability to successfully remove EVs from the blood is a powerful proof-of-concept, but the company's survival depends entirely on its ability to raise capital before its current cash reserves vanish. The transition from a research-heavy entity to a commercial-stage company is fraught with risks, including a history of material weaknesses in internal controls over financial reporting. Ultimately, the investment case hinges on the upcoming Australian clinical data and the company's ability to secure a strategic partner or additional funding. While the technical milestones are encouraging, the financial instability and the binary nature of the regulatory path create a high-risk profile for investors. The company's ability to remediate its internal control deficiencies and stabilize its balance sheet will be as critical as the clinical results themselves.